Recent News

Jun

23

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food...

Jun

14

- Study evaluates pre-administration of cold antibody prior to administration of imaging agent - Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is...

Jun

10

Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion's existing supply as company expands pipeline of actinium-based radio pharmaceuticals HAMILTON, ON and...

View All

Overview

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus fermentum urna dictum sem sollicitudin fringilla. Donec porttitor tristique congue. Vestibulum congue cursus nunc, at convallis augue pulvinar sit amet. Maecenas interdum rhoncus ullamcorper. Aliquam maximus purus in sapien bibendum, ac pulvinar ipsum venenatis. Praesent maximus sapien rhoncus massa tincidunt pretium. Vivamus ornare sem vitae purus efficitur luctus. Maecenas feugiat a lorem sit amet dignissim. Vestibulum varius tincidunt lobortis. Nulla maximus, nisi vitae tempus gravida, urna metus placerat diam, luctus mollis justo augue vel enim. Mauris condimentum convallis diam, eget sodales enim egestas sollicitudin. Donec vitae maximus risus, et euismod risus. Aliquam erat volutpat. Phasellus ultricies ac turpis nec dignissim. In auctor augue massa, vulputate ullamcorper ipsum ultricies non.

Stock Information
NASDAQFUSN
NEVER MISS AN UPDATE